Companies

Our website lists jobs from 1126 biotech startups.


+ Add your company



1–50 of 1126

Company

(click to see more info)
Short descriptionFoundedLocationClinical stageTherapy areaDrug typesDrug notesFundingInvestors
1. 1910 Genetics Computational chemistry platform to develop small molecule therapeutics2018Boston, MARDNeurological conditionsNEU, INF, IMM, ONC, RAR, GENUndisclosed programs RD infectious diseases, immunology conditions, oncology, rare & genetic diseases$22M A Mar 2021; $4.1M SeedFoundersX Ventures, Y Combinator, Scientia Ventures, Emles Advisors, Tuck Lye Koh of Shunwei Capital, M12
2. 20n Bio Computational Synthetic Biology2021Malvern, PA$3.3M seed Dec 2021BlueRun Ventures China
3. 3DBio Therapeutics Therapeutic-grade Bioprinting2014Long Island City, NY$5.3M A Apr 2021
4. 3T Biosciences TCR Therapies2017South SF, CARDSolid tumorsONC, IMM, VAC, INFUndisclosed programs RD autoimmune diseases, viral infections$40M A Aug 2022; $12M seed Oct 2017Westlake Village BioPartners, Lightspeed Venture Partners
5. 4D Molecular Therapeutics Gene Therapy2013Emeryville, CAClin1/Clin2Fabry diseaseGEN, OPH, RAR, LNG, GER, CVV4D-150 Clin1/Clin2 wet AMD, Clin0 DME; 4D-125 Clin1/Clin2 XLRP; 4D-110 Clin1/Clin2 choroideremia; 4D-710 Clin1/Clin2 cystic fibrosis, additional effort Clin0 cystic fibrosis; 4D-175 RD geographic atrophy; 4D-725 RD A1AT deficiency; undisclosed RD eye disease$138M stock May 2023; $222M IPO Dec 2020; $75M Jun 2020; $90M B Sep 2018; $20M prior
6. 64x Bio High throughput discovery and design of enhanced cell lines for next-generation biomanufacturing and therapeutics2018San Francisco, CA$55M A Jan 2022
7. 76Bio Targeted Protein Degraders2020Boston, MARDUndisclosed
8. A-Alpha Bio Yeast-based Drug Assay2017Seattle, WA$22.4M A2 Jul 2023; $20M A Sep 2021; $2.8M seed Sep 2019; $225 NSF grant Jul 2018
9. A2 Biotherapeutics Immunotherapy2017Agoura Hills, CAClin1Multiple cancersONCA2B694 Clin0 multiple cancers; 3 undisclosed programs RD undisclosed$71.5M B Oct 2020; $57M A Nov 2019
10. AAVogen Gene therapeutics to strengthen muscle and fight disease2015Rockville, MarylandClin0Inclusion body myositisMUS, NWL, GENAlso Clin0 cancer cachexia, RD DMD<10M
11. ACELYRIN Antibody MimeticAgoura Hills, CAClin3UveitisOPH, IMM, RHU, DRMAlso Clin3 hidradenitis suppurativa, Cin3 psoriatic arthritis, Clin2 axial spondyloarthritis; Lonigutamab Clin1 thyroid eye disease; XLRN-517 Clin0 urticaria
12. AI Proteins
13. AIRNA Bio RNA Editing TherapeuticsCambridge, MARDAlpha-1 antitrypsin deficiencyRAR, GENAlso RD undisclosed
14. ALX Oncology Immuno-oncology2015South SF, CAClin2 (fast track)Head & neck cancer (partner: Merck)ONCAlso different combo Clin2 (fast track) head & neck cancer (partner: MercK), Clin2 (fast track) gastric cancer (partner: Lilly), Clin1 urothelial cancer; 2 trials Clin1 breast cancer (one partnered: Zymeworks), Clin0 multiple myeloma; ALTA-002 Clin0 oncology$185.7M IPO Jul 2020; $105M C Feb 2020; $36M A Mar 2015
15. AN2 Therapeutics Novel medicines targeting infectious diseases2019Menlo Park, CAClin1NTM lung diseaseINFAlso 2 additional efforts Clin0/Clin1 NTM lung diseases, Clin0 melioidosis $70M stock Aug 2023; $79.4M IPO Mar 2022; $80M B Jan 2022; $12M A Nov 2019
16. AOA Dx Cancer Diagnosis2020Boulder, CO$7M Seed Sep 2022Avestria Ventures, AlleyCorp, The Helm, RH Capital, Olive Tree Capital, Tencent
17. ARTBIO Radioligand therapyOslo, NorwayClin0Prostate CancerONCABA RD solid tumors; ABB RD solid tumors
18. AUM BioTech RNA-silencing Products2015Philadelphia, PA
19. AVROBIO Cellular & Gene Therapies2016Cambridge, MAClin1/Clin2Gaucher disease type 1RAR, GEN, PEDAlso Clin0 Gaucher disease type 3; AVR-RD-04 Clin1/Clin2 cystinosis; AVR-RD-05 Clin0 Hunter syndrome; AVR-RD-03 Clin0 Pompe disease$100M IPO Feb 2020
20. Ab Studio Antibody humanization and optimization service2017Hayward, CA
21. Abalone Bio Antibody Therapies2017Emeryville , CAClin0Diabetic peripheral neuropathic painPN, LNG, INF, HEP, GI, ONC, NPH, END, NWLUndisclosed Clin0 liver fibrosis/NASH; undisclosed Clin0 lung conditions/influenza; undisclosed Clin0 IBD; 5 undisclosed programs RD immuno-oncology, polycystic kidney disease, obesity, diabetes
22. Abata Therapeutics Treg Cell Therapies2021Cambridge, MAClin0MSIMM, NEU, END, MUSUndisclosed programs RD diabetes (1), RD inclusion body myositis$95M A Jun 2021
23. Abeona Therapeutics Therapies for Sanfilippo (SF) Syndrome Type A and Type B.2013Cleveland, OHClin3 (fast track)Recessive dystrophic epidermolysis bullosa (ODD)GEN, DRM, PED, RAR, OPHAB0-504 RD/Clin0 Stargardt disease; ABO-503 RD/Clin0 x-linked retinoschisis; ABO-505 RD/Clin0 autosomal dominant optic atrophy; AIM Vectors RD undisclosed$25M stock Jul 2023; $35M stock Nov 2022; $25M stock Apr 2022
24. Abintus Bio Gene Therapy2020San Diego, CAClin0LymphomasONC, INF3 undisclosed programs RD oncology, infectious disease, undisclosed
25. Abiosciences
26. Absci
27. Accelevir Diagnostics
28. Accent Therapeutics RNA-modifying protein inhibitorsLexington, MAClin0Multiple cancersONC3 additional undisclosed programs RD/Clin0 multiple cancers; undisclosed programs RD undisclosed
29. Acepodia Antibody-Cell Conjugation TherapyAlameda, CAClin1Solid tumors (partner: JW Therapeutics)ONCACE1831 Clin1 hematological cancers; ACE2016 Clin0 oncology; ACE1708 RD solid tumors
30. Achieve Life Sciences Small MoleculesBothell, WAClin3Smoking cessationABUAlso 2 additional trials Clin2/Clin3 smoking cessation, Clin2 e-cigarette cessation
31. Acomhal Research 2017Roanoke, Virginia<10M
32. Acrivon Therapeutics Checkpoint InhibitorWatertown, MAClin2 (fast track)Ovarian cancerONCAlso Clin2 (fast track) endometrial cancer, Clin2 bladder cancer, 3 combo trials Clin2 multiple cancers; ACR-2316 RD/Clin0 oncology; 2 undisclosed programs RD oncology, undisclosed
33. Actym Therapeutics, Inc. Microbial-based immunotherapy platform2017Berkeley, CaliforniaClin0OncologyONC2 undisclosed programs RD oncology10 - 100M
34. Acutis Diagnostics
35. Adaptive Phage Therapeutics
36. Adcentrx Therapeutics Antibody drug conjugate San Diego, CAClin1Solid tumorsONCADRX-0405 Clin0 oncology; ADRX134 RD oncology; undisclosed programs RD oncology
37. Adicet Bio ImmunotherapiesRedwood City, CAClin1Non-Hodgkin's lymphoma, Lupus (FT)ONCADI-270 Clin0 renal cell carcinoma; ADI-925 Clin0 multiple cancers; ADI-002 Clin0 hepatocellular carcinoma; 3 undisclosed programs RD/Clin0 multiple cancers
38. Aditum Bio
39. Admera Health
40. Adverum Biotechnologies Adeno-Associated Virus Delivery, Gene TherapyRedwood City, CAClin2Wet AMDOPH, GER, GEN, NEUAlso additional Clin1 wet AMD; undisclosed (partner: GenSight) Clin2 retinitis pigmentosa; undisclosed (partner: Lexeo) Clin1 Friedreich's ataxia; ADVM-062 Clin0 blue cone monochromatism; 4 undisclosed programs RD/Clin0 geographic atrophy, retinitis pigmentosa
41. Aeglea BioTherapeutics
42. Aether Bio
43. Affini-T Therapeutics TCR Cell TherapyWatertown, MAClin0OncologyONCAFNT-211 Clin0 oncology; AFNT-212 Clin0 oncology; 4 undisclosed programs RD/Clin0 oncology
44. Affinia Therapeutics Gene DeliveryWaltham, MARDMuscle diseasesGEN, NEU, MUS, CVV, LNGAdditional undisclosed programs RD CNS diseases, cardiac conditions, genetic diseases, cystic fibrosis
45. Affinivax
46. AgBiome
47. Agastiya Biotech Small Molecules2019Temecula, CaliforniaClin3PsoriasisDRM, IMM, ONC, END, INFAB001 Clin2 solid tumors; ABREV01 Clin0 oncology; ABSGM003 RD/Clin0 diabetes; ABCIRT RD/Clin0 undisclosed; ABVIRO RD/Clin0 Dengue, COVID-19not disclosed
48. Agena Bioscience
49. AiViva Biopharma JEL delivery technology2016Newport Beach, CaliforniaClin1/Clin2Non-melanoma skin cancerONC, OPH, GER, UROAIV007-E02 Clin1/Clin2 wet AMD, DME: undisclosed Clin0 BPH, prostate cancer; undisclosed Clin0 solid tumorsnot disclosed
50. Ainnocence 2021San Francisco, Californianot disclosed

1–50 of 1126


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com